Drug Safety Settlement

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Bernanke Speaks

Bernanke Speaks

Bernanke touts benefits of easing, no hint of pullback.  Full Article 

Sensex Falls

Sensex Falls

Sensex falls for third day; L&T results spark worries.  Full Article 

Copper Shortage

Copper Shortage

Copper smelter closures put cable makers in tight spot.  Full Article 

Tax Avoidance

Tax Avoidance

Factbox: Apple, Amazon, Google and tax avoidance schemes.  Full Article 

Tracking India Gold

Tracking India Gold

Physical gold market awaits fresh import guidelines.  Full Article 

Earnings Season

Earnings Season

L&T looks overseas to offset weak home market  Full Article | Full Coverage 

Bank Acquisition

Bank Acquisition

Srei Infrastructure to buy Austrian bank unit - paper  Full Article 

Just Dial IPO

Just Dial IPO

Just Dial's 9.4 billion rupee IPO covered 11.6 times  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

REFILE-UPDATE 1-ONGC buys Hess stake in Azeri field for $1 bln

Related Topics

Stocks

   
Photo

Aishwarya at Cannes

Aishwarya Rai Bachchan marks 12 years at the Cannes Film Festival. Here is how she looked over the years.  Slideshow 

Sat Sep 8, 2012 2:07am IST

NEW YORK, Sept 7 (Reuters) - Hess Corp agreed to sell its 2.72 percent stake in the large Azeri, Chirag and Guneshli group of oil fields in Azerbaijan as well as its 2.36 percent stake in an associated pipeline to India's ONGC for $1 billion.

Hess said that ONGC's foreign investment arm ONGC Videsh will buy the assets in a deal it expects to close in the first quarter of 2013. It is subject to Indian and other regulatory approvals.

The BP-operated ACG oilfields are in the Caspian Sea around 100 kilometers east of Baku.

Rothschild advised ONGC Videsh on the sale.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.